Prenatal exposure to serotonin reuptake inhibitors and congenital heart anomalies: An exploratory pharmacogenetics studyDaud, A. N. A., Bergman, J. E. H., Kerstjens-Frederikse, W. S., van der Vlies, P., Hak, E., Berger, R. M. F., Groen, H. & Wilffert, B., 1-Jul-2017, In : Pharmacogenomics. 18, 10, p. 987-1001 15 p.
Research output: Contribution to journal › Article › Academic › peer-review
Aim: To explore the role of pharmacogenetics in determining the risk of congenital heart anomalies (CHA) with prenatal use of serotonin reuptake inhibitors.
Methods: We included 33 case-mother dyads and 2 mother-only (child deceased) cases of CHA in a case-only study. Ten genes important in determining fetal exposure to serotonin reuptake inhibitors were examined: CYP1A2, CYP2C9, CYP2C19, CYP2D6, ABCB1, SLC6A4, HTR1A, HTR1B, HTR2A and HTR3B.
Results: Among the exposed cases, polymorphisms that tended to be associated with an increased risk of CHA were SLC6A4 5-HTTLPR and 5-HTTVNTR, HTR1A rs1364043, HTR1B rs6296 and rs6298 and HTR3B rs1176744, but none reached statistical significance due to our limited sample sizes.
Conclusion: We identified several polymorphisms that might potentially affect the risk of CHA among exposed fetuses, which warrants further investigation.
|Number of pages||15|
|Publication status||Published - 1-Jul-2017|
- gene-environment interaction, heart defects, pharmacogenetics, serotonin reuptake inhibitors, teratogenicity, GENE-ENVIRONMENT INTERACTIONS, ANTIDEPRESSANT THERAPY, P-GLYCOPROTEIN, ABCB1 GENE, PROMOTER POLYMORPHISM, CLINICAL-RESPONSE, MAJOR DEPRESSION, PREGNANT-WOMEN, MEDICATION USE, RISK-FACTORS